Open Access<p>Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability</p>
Author(s) -
Wagner F. Gattaz,
Ricardo Saracco-Álvarez,
Claudiane Salles Daltio,
Martinus Theodorus van de Bilt,
José Ortegón,
Sergio J. Villaseñor-Bayardo,
Mário Rodrigues Louzã,
Hélio Elkis,
Bernardo Soares,
Patricia Cabrera Jaramillo,
Fábio Lorea Lawson,
Leonardo Díaz-Galvis
Publication year - 2020
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s233537
Subject(s) - paliperidone palmitate , medicine , tolerability , paliperidone , adverse effect , clinical endpoint , antipsychotic , schizophrenia (object oriented programming) , positive and negative syndrome scale , akathisia , randomized controlled trial , psychiatry , psychosis
Paliperidone palmitate is a long-acting, second-generation antipsychotic (SGA) indicated for the treatment of acute exacerbations and maintenance treatment of adults with schizophrenia. This study addressed the response to paliperidone palmitate in Latin American patients with acute symptoms and recently diagnosed schizophrenia.